The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Everyone here is waiting with baited breath for the Tox results. Every day we hope the red dot is going to land. What does Sareum do? bangs the drum for a share consolidation/dilution, rather than giving the people what they want. In the mean time the share price drifts as the tox results are still not available to be released. How on earth do they expect to get this consolidation through in these circumstances. Something is going on with this tox report, as they are trying to ram this consolidation through prior to the results being released. This makes no sense, the results should be released, and in the RNS details should be released to say why a consolidation is in everyone’s interests. That would be the most logical approach. What are you up to Sareum, trying to force a consolidation through before spilling the beans
How on earth can I be expected to vote yes when I have no idea what I’m voting for.. As in all aspects of life you can only make an informed decision when your presented with facts, and a plan for the future. As things stand neither of these have be presented which borders on insulting to all share holders. If you want this to pass through Sar you have to start explaining what you hope to achieve. I’m willing to vote yes but at least give us something to go on.
Something to keep us all focused and a recap on why all of us were getting excited in December before the frustrations crept in.
AIM-listed Sareum Holdings (AIM:SAR) has issued a bullish update to investors today on progress with its SDC-1801 COVID treatment, which continues to advance towards first clinical trial. The board also said it felt the company was in a robust position financially following several share subscriptions by high-net-worth individuals during 2021.
In addition, the company said it is highly optimistic about the future of its out-licensed asset SRA737, which is expected to enter new clinical trials in 2022 under the guidance of Sierra Oncology, the licence holder for this exciting candidate.
SDC-1801 is a selective dual tyrosine kinase 2/Janus kinase 1 inhibitor, discovered by Sareum. The company has been advancing SDC-1801 through preclinical development and preparing for clinical trials to investigate its potential for treating autoimmune diseases, such as psoriasis, lupus, inflammatory bowel diseases, rheumatoid arthritis as well as severe respiratory symptoms of Covid-19.
Sareum is prepping for clinical trials in 2022
“We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation have been completed and we expect the finalised reports in the first quarter of 2022,” the board told investors today. “The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801.”
Sareum has appointed consultants to advise on the design of these first clinical trials, which would investigate the safety of SDC-1801 in healthy volunteers during which time the company will continue to assess the initial indications for further study.
The synthesis of SDC-1801 drug substance under GMP conditions, intended for use in the planned Phase 1 clinical trial, continues to progress to plan with delivery expected during the first half of 2022.
Oral capsule formulation for Covid symptoms?
Sareum has also initiated the process to develop drug product for these trials as an oral capsule formulation rather than orally dosed solutions or suspensions as previously planned. This step will require additional time, but the company says it believes it to be a good use of resources that will add value to the programme by improving the quality of the data generated in the Phase 1 trial and remove the need to develop capsules at a later stage.
Importantly, this first clinical trial could also support the clinical development of SDC-1801 as a potential treatment for the severe respirato
Are we still talking about this subject? Look the guy has been around since day dot, his posts are very positive, and his knowledge is impressive. However if anyone here including him starts throwing around valuations of £40 a share, and having drunken rants that make no sense at 2am then your going to her ridiculed. It’s not personal but you lose credibility. Come on let’s move on….
We are fearg, it’s not worth voicing it though as the usual suspects come out with the predictable comments, “empty vessels” “sell up” etc. I believe If Sareum said we are not going to progress our compounds for another 10 years you would still get sone people here saying it’s a good thing. There is absolutely nothing wrong calling out a wrong when you see it, we will all make a small fortune in the future I honestly believe it with Sareum, but be honest with yourselves when we are being wronged
I’ll be voting against it. My gut feeling is exactly what SOG highlighted. They will consolidate the share, they will then release a glut of extra shares after, to increase the war chest massively diluting all existing shares holders. This will all be done under the proviso of hinting at honey for all invested in the future. If you can’t see this you need your head examining. Here is an idea, release the tox results and then give us all an explanation, a proper explanation on why this is good for the company. At the moment your asking us to vote for something blindly, when all we see is our investments getting whittled away on a daily basis
Extra dilution just what we need, in no form is this positive. Wish Sareum would just get on with the task at hand, rather than all this faffing around in the back ground meddling rather than getting on with the science, ie this elusive tox report that we keep being teased with.
Look how the price is getting walked down daily, feargs summary was spot on re it’s performance. When an RNS lands re a consolidation I can see this share price getting smashed to pieces in the short term. SOG leaned towards the carnage, admittedly it will be short term, but a great opportunity to load up again, as uncomfortable as this is 3p is not out of the question in the coming weeks.
Thankyou to all those who replied. Some very interesting points made on both sides of the coin re investing prior or after consolidation. SOG I am leaning towards your side of the coin. I have been invested here for just short of 2 years now. One thing which I have noticed with this share, is the slightest neutral/uncertain RNS that is released, this then causes the share price to get massively manipulated, it always rebounds again, but it gets punished severely in the short term. Seeing this pattern on numerous occasions I am leaning towards keeping my 20k out until after consolidation and then jumping in when the silly games start. Food for thought though, as Hotblack makes a couple of good points. Consolidation is not nailed on here, but is looking very likely and also by holding back further investment, you miss out on any pending good news which is on the horizon as we all know. I suppose it comes down to a very simple question. Would I be happy to miss out on potential gains by holding back investment and missing out on a rise from positive news, or would I prefer to get my investment in before the consolidation but risk seeing it depreciate in the short term mm games. With a holding of 1.5 million shares to date the first option is definitely the more palatable to me. Very thought provoking never the less.
SD, I won’t take it as investment advice, merely intrigued. I’m going to research this further but wanted to get your thoughts. I’ll be popping another £20k in (Yearly ISA allowance). I’m torn if the share price drops below 5p then I always planned to invest it then. However with the share price likely to be consolidated, I have noticed in the past the price drops in relevant terms before rebounding. I’m now thinking maybe try and catch this bounce. Any thoughts, as you seem to be in a similar position.
I’m very much against consolidation. Completely unnecessary, very rare to come through the process and then realise you are better off, never going to happen. People justify it so say it makes it more attractive to investors, absolute codswollop. No one invests based on how the share price looks you invest because of potential for a return on your investment. Of course the risk further down the line is further dilution. Looking at the company now we have £6 million in the bank, with potential for agile funding. Sareum never intend to take their products to market they confirmed this already, so the reason for consolidation is smoke and mirrors and completely unnecessary. None of us will be better off from consolidation itself, it will be the science.
You may be happy with the 6p today but next week the slow drift starts again, it’s a cycle that seems to keep repeating itself we just need a bit of momentum, the confidence is here so we should be seeing small daily gains to reflect this.